This study [7] was published before the initial clinical trials of GLP-1 receptor agonists [11, 12] and allowed this novel therapy to be viewed as a replacement for what appeared to be lacking in people with type 2 diabetes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.